(Source: PRNewswire-FirstCall)
FRAZER, Pa., Feb. 4 /PRNewswire-FirstCall/ -- Cephalon, Inc. announced today that Sarma P. Duddu, Ph.D., has been appointed as General Manager and Vice President of Drug Delivery Technologies of CIMA LABS, Inc. In this role, Dr. Duddu will lead all aspects of the Cephalon drug delivery business at CIMA, its wholly owned drug delivery subsidiary located in suburban Minnesota.
(Photo: http://www.newscom.com/cgi-bin/prnh/20090204/PH66729 )
In his new role, Dr. Duddu will be a member of the Cephalon Technical Operations leadership team and will report directly to Peter E. Grebow, Ph.D., Executive Vice President of Worldwide Technical Operations.
"We are pleased with the strong record of successful drug development that Sarma brings to our organization," said Peter Grebow, Ph.D., Executive Vice President Worldwide Technical Operations. "His extensive experience in drug delivery and previous leadership roles in R&D, product development and new product research make him well qualified to not only lead, but to strengthen and grow our drug delivery business."
Dr. Duddu has more than 15 years of pharmaceutical experience and has been involved in all aspects of the drug delivery business. Most recently, he held the position of vice president of pharmaceutical development at Nektar Therapeutics (formerly Inhale Therapeutic Systems) based in San Carlos, CA. Previously at Nektar, Dr. Duddu held key management positions in product development, R&D operations, corporate development and strategy, as well as new product research. Prior to Nektar, he worked at SmithKline Beecham Pharmaceuticals in King of Prussia, PA, where he focused in the areas of pharmaceutical technology formulation sciences and product development.
Dr. Duddu earned a Ph.D. in Pharmaceutics from the University of Minnesota and a Bachelors degree in Pharmacy from Andhra University in Waltair, India.
About CIMA LABS INC.
CIMA LABS INC. is the third largest drug delivery company in the United States. The company is primarily focused on research and development of drug delivery technologies for pharmaceutical products. Its drug delivery technologies include OraSolv(R)and DuraSolv(R) orally disintegrating tablet (ODT), Lyoc(R), Microsolv(R), OraVescent(R), and OTC(R) (oral transmuscosal). Cephalon currently manufactures the following products in the U.S. that use CIMA drug delivery technology: FENTORA(R) (fentanyl buccal tablet) [C-II] and ACTIQ(R) (oral transmucosal fentanyl citrate) [C-II].
In addition, eight prescription and three over-the-counter products are distributed globally by its pharmaceutical partners. For more information please visit http://www.cimalabs.com/.
About Cephalon, Inc.
